Bailard, Inc. Intra Cellular Therapies, Inc. Transaction History

Bailard, Inc.

$3.58 Billion
Q1 2024

A detailed history of Bailard, Inc. transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Bailard, Inc. holds 15,480 shares of ITCI stock, worth $1.08 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

15,480

Previous 17,080 9.37%

Holding current value

$1.08 Million

Previous $1.22 Million 12.43%

% of portfolio

0.03%

Previous 0.04%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 08, 2024	SELL	$64.37 - $75.65 $102,992 - $121,040	-1,600 Reduced 9.37%	15,480 $1.07 Million
Q4 2023 Feb 02, 2024	BUY	$46.37 - $73.65 $9,274 - $14,730	200 Added 1.18%	17,080 $1.22 Million
Q2 2023 Jul 20, 2023	BUY	$54.67 - $66.44 $76,538 - $93,016	1,400 Added 9.04%	16,880 $1.07 Million
Q1 2023 May 08, 2023	SELL	$43.8 - $56.99 $639,480 - $832,054	-14,600 Reduced 48.54%	15,480 $838,000
Q4 2022 Feb 02, 2023	SELL	$44.07 - $54.45 $92,547 - $114,345	-2,100 Reduced 6.53%	30,080 $1.59 Million

Q4 2021 Feb 10, 2022	SELL	$35.2 - $53.42 $4.44 Million - $6.73 Million	-126,000 Reduced 79.66%	32,180 $1.68 Million
Q3 2021 Nov 15, 2021	SELL	$28.72 - $42.49 $388,294 - $574,464	-13,520 Reduced 7.87%	158,180 $5.9 Million
Q1 2021 May 13, 2021	BUY	$30.8 - $39.51 $12,320 - $15,804	400 Added 0.23%	171,700 $5.83 Million
Q4 2020 Feb 03, 2021	BUY	$23.34 - $32.22 $917,262 - $1.27 Million	39,300 Added 29.77%	171,300 $5.45 Million
Q3 2020 Nov 10, 2020	SELL	$17.61 - $31.86 $158,490 - $286,740	-9,000 Reduced 6.38%	132,000 $3.39 Million
Q2 2020 Aug 12, 2020	BUY	$14.35 - $26.64 $2.02 Million - $3.76 Million	141,000 New	141,000 $3.62 Million

Others Institutions Holding ITCI

# of Institutions

381

Shares Held

77.7M

Call Options Held

1.7M

Put Options Held

1.13M

View Full List

About Intra-Cellular Therapies, Inc.

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $6.57B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

More about ITCI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bailard, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Bailard, Inc. with notifications on news.

Account